Previous 10 | Next 10 |
Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023 Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a seco...
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy U.S. Food and Drug Administration approval represents a potential significant driver of JEMPERLI royalties Anticipate top-line data from two GSK...
2023-07-07 10:33:28 ET Summary AnaptysBio, Inc. had major deals with big pharma in past years. However, its current programs are not that convincing. They have a lot of cash from earlier deals. AnaptysBio, Inc. ( ANAB ) is a late-stage developer of immune the...
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its sen...
2023-05-20 10:30:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
2023-05-18 10:18:35 ET TD Cowen launched its coverage on the clinical-stage biotech AnaptysBio ( NASDAQ: ANAB ) with an Outperform rating on Thursday, projecting its anti-inflammatory candidates rosnilimab and ANB032 to generate $1.5B in peak U.S. sales. Rosnilimab, AnaptysBio...
2023-05-11 17:33:56 ET AnaptysBio press release ( NASDAQ: ANAB ): Q1 GAAP EPS of -$1.58 misses by $0.53 . Revenue of $1.4M (+44.3% Y/Y) misses by $1.48M . Cash, cash equivalents and investments totaled $526.1 million as of March 31, 2023, compared to $584....
Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist Hosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023 Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agoni...
Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4 Flare control sustained on monthly subcutaneous doses through Week 16 Imsidolimab was generally safe and well tolerated with low overall ADA incidence Top-line GEMI...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...